The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
Open accessAbstract
Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine. These drugs provide symptomatic relief but poorly affect the progression of the disease. Drug discovery has been directed, in the last 10 years, to develop ‘disease modifying drugs’ hopefully able to counteract the progression of AD. Because in a chronic, slow progressing pathological process, such as AD, an early start of treatment enhances the chance of success, it is crucial to have biomarkers for early detection of AD‐related brain dysfunction, usable before clinical onset. Reliable early biomarkers need therefore to be prospectively tested for predictive accuracy, with specific cut off values validated in clinical practice. Disease modifying drugs developed so far include drugs to reduce β amyloid (Aβ) production, drugs to prevent Aβ aggregation, drugs to promote Aβ clearance, drugs targeting tau phosphorylation and assembly and other approaches. Unfortunately none of these drugs has demonstrated efficacy in phase 3 studies. The failure of clinical trials with disease modifying drugs raises a number of questions, spanning from methodological flaws to fundamental understanding of AD pathophysiology and biology. Recently, new diagnostic criteria applicable to presymptomatic stages of AD have been published. These new criteria may impact on drug development, such that future trials on disease modifying drugs will include populations susceptible to AD, before clinical onset. Specific problems with completed trials and hopes with ongoing trials are discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Reddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease
Laxton, A. W., Tang‐Wai, D. F., McAndrews, M. P., Zumsteg, D., Wennberg, R., Keren, R., Wherrett, J., Naglie, G., Hamani, C., Smith, G. S., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22089 · Cited by 812
Tau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Nuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 612
Watson, G. S. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 597
Ohno, M., Sametsky, E. A., Younkin, L. H., Oakley, H., Younkin, S. G., Citron, M., Vassar, R., & Disterhoft, J. F. (2004) · Neuron · doi:10.1016/s0896-6273(03)00810-9 · Cited by 549
Clearing the brain's amyloid cobwebs
Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., & Perl, D. P. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540250089017 · Cited by 514
Shen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485
Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Eriksdotter Jönhagen, M., Nordberg, A., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
β-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421
Self-citationPBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1390 · Cited by 405
Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080044 · Cited by 402
Caricasole, A., Copani, A., Caraci, F., Aronica, E., Rozemuller, A. J., Caruso, A., Storto, M., Gaviraghi, G., Terstappen, G. C., & Nicoletti, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1381-04.2004 · Cited by 398
Self-citationLithium and risk for Alzheimer's disease in elderly patients with bipolar disorder
Nunes, P. V., Forlenza, O. V., & Gattaz, W. F. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029868 · Cited by 368
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Therapeutic approaches to Alzheimer's disease
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Bench to Bedside: The Quest for Quality in Experimental Stroke Research
Dirnagl, U. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600298 · Cited by 349
Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study
Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H., & Launer, L. J. (2002) · Neurology · doi:10.1212/wnl.58.11.1629 · Cited by 338
Olson, L., Nordberg, A., von Holst, H., Bäckman, L., Ebendal, T., Alafuzoff, I., Amberla, K., Hartvig, P., Herlitz, A., Lilja, A., et al. (1992) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02257624 · Cited by 323
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 322
Dodel, R. C. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., Lacombe, D., Kong, X., Aman, A., Laurin, J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.015 · Cited by 307
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301
TMP21 is a presenilin complex component that modulates γ-secretase but not ɛ-secretase activity
Chen, F., Hasegawa, H., Schmitt-Ulms, G., Kawarai, T., Bohm, C., Katayama, T., Gu, Y., Sanjo, N., Glista, M., Rogaeva, E., et al. (2006) · Nature · doi:10.1038/nature04667 · Cited by 301
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04606 · Cited by 295
Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287
Endogenous amyloid‐β is necessary for hippocampal synaptic plasticity and memory
Puzzo, D., Privitera, L., Fa', M., Staniszewski, A., Hashimoto, G., Aziz, F., Sakurai, M., Ribe, E. M., Troy, C. M., Mercken, M., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22313 · Cited by 278
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Methylene blue and Alzheimer's disease
Oz, M., Lorke, D. E., & Petroianu, G. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.034 · Cited by 257
Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease
Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1102 · Cited by 224
Lichtenthaler, S. F., Haass, C., & Steiner, H. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07248.x · Cited by 205
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
Aisen, P. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., & Garceau, D. (2006) · Neurology · doi:10.1212/01.wnl.0000244346.08950.64 · Cited by 201
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype
Gibson, G. E., Haroutunian, V. H., Zhang, H., Park, L. C. H., Shi, Q., LESSER, M. L., Mohs, R. C., Sheu, R., & Blass, J. P. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3<297::aid-ana3>3.0.co;2-z · Cited by 197
Pathways by Which Aβ Facilitates Tau Pathology
Blurton-Jones, M., & LaFerla, F. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025242 · Cited by 195
P. Imbimbo, B., & A.M. Giardina, G. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795860942 · Cited by 194
Neuropsychiatric symptoms in dementia: Importance and treatment considerations
Ballard, C. G., Day, S., Sharp, S. I., Wing, G., & Sorensen, S. (2008) · International Review of Psychiatry · doi:10.1080/09540260802099968 · Cited by 179
Martone, R. L., Zhou, H., Atchison, K. P., Comery, T. A., Xu, J. Z., Huang, X., Gong, X., Jin, M., Kreft, A. F., Harrison, B. L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152975 · Cited by 179
RAGE and Alzheimer's Disease: A Progression Factor for Amyloid-β-Induced Cellular Perturbation?
Yan, S. D., Bierhaus, A., Nawroth, P. P., & Stern, D. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1030 · Cited by 177
Nerve inflammation halts trial for Alzheimer's drug
Check, E. (2002) · Nature · doi:10.1038/415462a · Cited by 176
A feasibility and tolerability study of lithium in Alzheimer's disease
Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 175
Wu, H.-M., Tzeng, N.-S., Qian, L., Wei, S.-J., Hu, X., Chen, S.-H., Rawls, S. M., Flood, P., Hong, J.-S., & Lu, R.-B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.64 · Cited by 174
Mandel, S. A., Amit, T., Kalfon, L., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15207 · Cited by 173
Reiman, E. M., Langbaum, J. B. S., & Tariot, P. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.91 · Cited by 170
Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903044982 · Cited by 168
Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles
Iqbal, K., Alonso, A. D. C., Gong, C., Khatoon, S., Pei, J. ‐., Wang, J. Z., & Grundke, I. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_15 · Cited by 166
Alzheimer's failure raises questions about disease-modifying strategies
Extance, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3288 · Cited by 165
Assembly, Trafficking and Function of γ-Secretase
Kaether, C., Haass, C., & Steiner, H. (2006) · Neurodegenerative Diseases · doi:10.1159/000095267 · Cited by 162
Lithium: Potential Therapeutics Against Acute Brain Injuries and Chronic Neurodegenerative Diseases
Wada, A., Yokoo, H., Yanagita, T., & Kobayashi, H. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj05009x · Cited by 161
Disease-modifying trials in Alzheimer's disease: a European task force consensus
Vellas, B. J., Andrieu, S., Sampaio, C., & Wilcock, G. K. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70677-9 · Cited by 157
Valproate preparations for agitation in dementia
Lonergan, E., & Luxenberg, J. S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003945.pub3 · Cited by 155
Caraci, F., Battaglia, G., Bruno, V., Bosco, P., Carbonaro, V., Giuffrida, M. L., Drago, F., Sortino, M. A., Nicoletti, F., & Copani, A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00115.x · Cited by 154
Self-citationSecretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 154
Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease
Nordberg, A. K. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213804.59187.2d · Cited by 151
Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Imbimbo, B. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783334015 · Cited by 143
Gauthier, S. G., Aisen, P. S. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., Garceau, D., Suhy, J., Oh, J., Lau, W. C., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0106-x · Cited by 139
Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology
Fenili, D., Brown, M., Rappaport, R. V., & McLaurin, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0156-7 · Cited by 136
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 134
Aspartic Proteases in Drug Discovery
Eder, J., Hommel, U., Cumin, F., Martoglio, B., & Gerhartz, B. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313560 · Cited by 134
RAGE regulates BACE1 and Aβ generation via NFAT1 activation in Alzheimer's disease animal model
Cho, H. J., Son, S. M., Jin, S. M., Hong, H. S., Shin, D. H., Kim, S. J., Huh, K. H., & Mook‐Jung, I. (2009) · The FASEB Journal · doi:10.1096/fj.08-126383 · Cited by 130
Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease: Rationale and Current Evidence
Dodel, R. C., Neff, F., Noelker, C., Pul, R., Du, Y., Bacher, M., & Oertel, W. H. (2010) · Drugs · doi:10.2165/11533070-000000000-00000 · Cited by 125
Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity.
Rabizadeh, S., Bitler, C. M., Butcher, L. L., & Bredesen, D. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10703 · Cited by 121
Mandel, R. J. (2010) · PubMed · Cited by 121
β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic mice
Chang, W., Huang, X., Downs, D., Cirrito, J. R., Koelsch, G., Holtzman, D. M., Ghosh, A. K., & Tang, J. (2010) · The FASEB Journal · doi:10.1096/fj.10-167213 · Cited by 115
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
Magga, J. M., Puli, L., Pihlaja, R., Kanninen, K. M., Neulamaa, S., Malm, T., Härtig, W., Grosche, J., Goldsteins, G., Tanila, H., et al. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-90 · Cited by 111
Kalinin, S., Richardson, J. C., & Feinstein, D. L. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207949 · Cited by 107
Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease
Cattaneo, A., Capsoni, S., & Paoletti, F. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15210 · Cited by 103
What the halted phase III γ‐secretase inhibitor trial may (or may not) be telling us
Schor, N. F. (2011) · Annals of Neurology · doi:10.1002/ana.22365 · Cited by 101
Борисович, Б. И. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.8.1500435 · Cited by 100
Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Cerpa, W. F., Dinamarca, M. C., & Inestrosa, N. C. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533321 · Cited by 100
Imbimbo, B. P., Hutter‐Paier, B., Villetti, G., Facchinetti, F., Cenacchi, V., Volta, R., Lanzillotta, A., Pizzi, M., & Windisch, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00097.x · Cited by 98
Kerchner, G. A., & Boxer, A. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.493872 · Cited by 98
Developing novel immunogens for a safe and effective Alzheimer's disease vaccine
Lemere, C. A. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17506-4 · Cited by 90
Abnormal Mitochondrial Dynamics—A Novel Therapeutic Target for Alzheimer's Disease?
Su, B., Wang, X., Bonda, D., Perry, G. L., Smith, M. A., & Zhu, X. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8095-7 · Cited by 90
Bishop, K. M., Hofer, E. K., Mehta, A., Ramirez, A., Sun, L., Tuszynski, M. H., & Bartus, R. T. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.03.004 · Cited by 89
Dimebon (Latrepirdine) Enhances Mitochondrial Function and Protects Neuronal Cells from Death
Zhang, S., Hedskog, L., Petersen, C. H., Winblad, B. G., & Ankarcrona, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100174 · Cited by 88
Valproate preparations for agitation in dementia
Lonergan, E., & Luxenberg, J. S. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003945.pub2 · Cited by 87
The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
Schmidt, A. M., Sahagan, B. G., Nelson, R. B., Selmer, J., Rothlein, R., & Bell, J. M. (2009) · PubMed · Cited by 86
Wischik, C. M., & Staff, R. T. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0046-5 · Cited by 86
Prevention trials in Alzheimer's disease: An EU-US task force report
Vellas, B. J., Aisen, P. S. S., Sampaio, C., Carrillo, M. C., Scheltens, P., Scherrer, B., Frisoni, G. B., Weiner, M. W., Schneider, L. S. S., Gauthier, S. G., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.014 · Cited by 85
Nagahara, A. H., Bernot, T., Moseanko, R., Brignolo, L. L., Blesch, A., Conner, J. M., Ramirez, A., Gasmi, M., & Tuszynski, M. H. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.10.004 · Cited by 84
Psychopharmacological Neuroprotection in Neurodegenerative Disease: Assessing the Preclinical Data
Lauterbach, E. C., Victoroff, J., Coburn, K. L., Shillcutt, S. D., Doonan, S. M., & Mendez, M. F. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.1.8 · Cited by 82
PPARγ transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons
Du, J., Zhang, L., Liu, S., Zhang, C., Huang, X., Li, J., Zhao, N., & Wang, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.047 · Cited by 69
The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease
Amijee, H., & Scopes, D. I. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1044 · Cited by 68
Saumier, D., Duong, A., Haine, D., Garceau, D., & Sampalis, J. S. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0217-4 · Cited by 62
Robert, R., Dolezal, O., Waddington, L. J., Hattarki, M. K., Cappai, R., Masters, C. L., Hudson, P. J., & Wark, K. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn052 · Cited by 61
Preclinical studies of human disease: Time to take methodological quality seriously
van der Worp, H. B., & Macleod, M. R. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.04.008 · Cited by 61
Amyloid Oligomer Neurotoxicity, Calcium Dysregulation, and Lipid Rafts
Malchiodi‐Albedi, F., Paradisi, S., Matteucci, A., Frank, C., & Diociaiuti, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/906964 · Cited by 60
Prevention of dementia: lessons from SYST-EUR and PROGRESS
Hanon, O., & Forette, F. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.015 · Cited by 59
Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease
Wısnıewskı, T., & Frangione, B. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00102.x · Cited by 58
The use of mass spectrometry to study amyloid‐β peptides
Grasso, G. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20281 · Cited by 57
Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?
Tariot, P. N., & Aisen, P. S. S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09com05331 · Cited by 55
Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Paris, F., Santamato, A., D’Onofrio, G., Logroscino, G., Pilotto, A., & Solfrizzi, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511798192718 · Cited by 54
Memapsin 2 (Beta-Secretase) Inhibitors: Drug Development
Ghosh, A. K., Kumaragurubaran, N., Ling, H., Koelsch, G., & Tang, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954730 · Cited by 54
Pharmacodynamics and Pharmacokinetics of the γ-Secretase Inhibitor PF-3084014
Lanz, T. A., Wood, K. M., Richter, K. E. G., Nolan, C. E., Becker, S. L., Pozdnyakov, N., Martin, B., Du, P., Oborski, C., Wood, D. E., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167379 · Cited by 50
Nilvadipine prevents cognitive decline of patients with mild cognitive impairment
Hanyu, H., Hirao, K., Shimizu, S., Sato, T., Kiuchi, A., & Iwamoto, T. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1851 · Cited by 48
Kokjohn, T. A., & Roher, A. E. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847315 · Cited by 47
Alternative Aβ Immunotherapy Approaches for Alzheimers Disease
Town, T. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787847306 · Cited by 45
Kennelly, S., Abdullah, L. I., Paris, D., Parish, J., Mathura, V. S., MULLAN, M. J., Crawford, F., LAWLOR, B. A., & Kenny, R. A. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2638 · Cited by 42
Possible Involvement of Programmed Cell Death Pathways in the Neuroprotective Action of Polyphenols
Bastianetto, S., Krantic, S. M., Chabot, J., & Quirion, R. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391854 · Cited by 42
Progress in the Development of β-secretase Inhibitors for Alzheimer's Disease
Albert, J. S. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04804-8 · Cited by 38
Yan, C., Liang, Y. S., Nylander, K. D., Wong, J., Rudavsky, R. M., Saragovi, H. U., & Schor, N. F. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12320-6 · Cited by 36
Lambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29
Yeh, H., & Tsai, S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.03.049 · Cited by 28
The Discovery and Role of CD147 as a Subunit of gamma-Secretase Complex
Zhou, S., Zhou, H., Walian, P. J., & Jap, B. K. (2006) · Drug News & Perspectives · doi:10.1358/dnp.2006.19.3.985932 · Cited by 24
Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Aβ42
Persaud‐Sawin, D., Banach, L., & Harry, G. J. (2008) · Glia · doi:10.1002/glia.20759 · Cited by 24
Dementia screening, biomarkers and protein misfolding: Implications for public health and diagnosis
Galvin, J. E. (2011) · Prion · doi:10.4161/pri.5.1.14439 · Cited by 24
How can we recognize “disease modification” effects?
Siemers, E. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0036-7 · Cited by 24
Inherent Anti-amyloidogenic Activity of Human Immunoglobulin γ Heavy Chains
Adekar, S. P., Klyubin, I. V., Macy, S., Rowan, M. J., Solomon, A., Dessain, S. K., & O’Nuallain, B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.044321 · Cited by 22
Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation
Ringman, J. M., Taylor, K., Teng, E., Coppola, G., & Gylys, K. H. (2011) · Neurology · doi:10.1212/wnl.0b013e31821f4488 · Cited by 13
Wang, S., & Jia, J. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30968 · Cited by 12
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Bioactive Benzofuran derivatives: A review
Khanam, H., & Shamsuzzaman (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.039 · Cited by 554
The Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
Metadata
- Authors
- Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-03-12
- Volume
- 73
- Issue
- 4
- Pages
- 504-517
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1551854265
- Cited by
- 309
- References
- 152
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.